Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts RVMD Hot Sheet
Join SI Premium – FREE
Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($3.06), $1.10 worse than the analyst estimate of ($1.96).
For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransUnion (TRU) Tops Q3 EPS by 4c; Offers FY26 EPS Guidance
- Hycroft Mining reports Q3 2026 results with $211M cash, no debt
- Polaris Industries (PII) Tops Q3 EPS by 49c, Beats on Revenue; Offers Strong FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
